Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$14.44 USD

14.44
1,190,769

+0.16 (1.12%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Quest Diagnostics (DGX) Q4 Earnings Top Estimates, Margin Down

Improvement within Quest Diagnostics' (DGX) legacy base business contributes to Q4 performance.

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Drop

Align Technology's (ALGN) lower scanner volume and ASPs are partially offset by higher services revenues from the larger installed base of scanners and increased non-system revenues.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.

Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up

Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.

Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?

Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.

Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth

Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).

HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates

HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Healthy Top-Line Growth Buoy Jabil (JBL) Q1 Earnings?

Backed by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics, Jabil (JBL) is likely to record healthy fiscal first-quarter revenues.

Neogen's (NEOG) Synergize Disinfectant Now Widely Available

Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.

Neogen (NEOG) Down 13.6% Since Last Earnings Report: Can It Rebound?

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips

Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.

Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates

Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Neogen (NEOG) Launches Test for Detection of Cashew Allergen

Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).

Neogen (NEOG) Finalizes Food Safety Business Merger With 3M

The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.

Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates

Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down

Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.